ORIC
$11.16+0.06 (+0.54%)
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a...
Recent News
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.
Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns
In recent days, Oric Pharmaceuticals has come under pressure after Ipsen voluntarily withdrew its EZH2 inhibitor Tazverik from the market due to secondary hematologic malignancy concerns in a confirmatory study, prompting questions about similar mechanisms in oncology. Oric has emphasized that its PRC2 inhibitor rinzimetostat is mechanistically distinct from Tazverik and has shown no malignancies in animal toxicity studies, a point several analysts highlight as they reaffirm confidence in...
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Recent Share Price Volatility
What recent returns say about ORIC Pharmaceuticals With no single headline event driving attention today, ORIC Pharmaceuticals (ORIC) has still caught investor interest after a mix of short term pullbacks and longer term gains across the month and past 3 months. See our latest analysis for ORIC Pharmaceuticals. At a share price of $11.76, ORIC has seen a 1-day share price return decline of 6.59% and a 7-day share price return decline of 15.09%. Its 30-day and year to date share price returns...
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained
Wall Street is drawing fresh lines across the large-cap biopharma landscape. Jefferies initiated coverage on Gilead Sciences Inc. (NASDAQ:GILD) with a Buy rating and a $180 price target, while assigning a Hold and a $350 price target to Amgen Inc. (NASDAQ:AMGN). Meanwhile, JPMorgan maintained its Overweight rating on clinical-stage oncology company Oric Pharmaceuticals Inc. (NASDAQ:ORIC) ... Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Expla
After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?